Clinuvel Pharmaceuticals Limited

For the half year ended 31 December 2025, CLINUVEL said sales revenue rose 4% year over year to just under $37 million, interest income increased 14% to $5.3 million, and cash reserves increased by $9 million to $233 million. The company said expenses were up 22%, net assets increased by $8.2 million to just under $250 million, and this was the 20th consecutive profit since commercial operations began. Management did not give EPS or gross margin figures on the call. Forward guidance was for full-year spending of about $55 million to $58 million excluding capital expenditures, and the company said second-half revenue is usually proportionately higher than the first half; it also expects CUV105 top-line results in the second half of 2026, CUV107 to start, and preclinical peptide-formulation results later this year.

Philippe Wolgen framed the company as following a gradual, deliberate strategy that requires tight financial control and sustained cash generation. He said the recent spending increase was intentional and tied to R&D, the vitiligo program, regulatory filings, and internal capability-building, and he described the current model as working well. He also emphasized optionality and cash as central to the plan, arguing the company is building toward a diversified, sustainable enterprise.

Peter Vaughan highlighted steady operating performance, saying revenues were up 4%, sales revenue reached just under $37 million, and the company posted its 20th consecutive profit. He pointed to higher expenses tied to expansion: personnel expense up 16%, commercial distribution up 42%, finance/corporate/legal up 47%, and other expenses up 191%, while noting non-cash expenditure was down and share-based payments were lower under a new 1-year share plan. On the balance sheet, he said cash rose to $233 million, net assets were just under $250 million, the company is debt-free for 21 consecutive years, and average term deposits were about 300 days at an average yield of about 4.5%.

Analysts focused on the vitiligo filing path, the ACTH/NEURACTHEL strategy, the impact of Disc Medicine’s FDA setback, NASDAQ reporting changes, Medicaid exposure, and the U.S./non-U.S. sales mix. Management said it intends to complete CUV105 and CUV107 before filing for vitiligo, plans to file first with the EMA and then the FDA, and believes the EMA route is more supportive for its novel approach. On ACTH, Philippe said NEURACTHEL would first be filed in Europe via mutual recognition before the U.S. and that Europe offers a more direct commercial route in specialty centers. On the FDA’s Bitopertin decision, management argued it reinforces CLINUVEL’s position as the only approved EPP treatment in the U.S. with proven safety and efficacy, while Linda Teng said she would not comment on competitors but reiterated the importance of meaningful patient benefit. For reporting, Peter said the NASDAQ uplist would not change filing frequency, only currency and U.S. GAAP reporting.